Transcript Presentation Title Here Presentation Subtitle Here

TB Pathogenesis
Stacey Rizza, M.D.
©2013 MFMER | slide-1
Disclosures
• None
©2013 MFMER | slide-2
Objectives
• Explain how M. tuberculosis is transmitted
• Describe the immune response to M.
tuberculosis
• Understand the targets of immunotherapies for
M. tuberculosis
©2013 MFMER | slide-3
Whatever happened to the good old days: you
know, dirty attics, tuberculosis and general
all-round suffering? (Sir Arnold Wesker)
How Old is M. tuberculosis?
1. 150 years
2. 325 years
3. 550 years
4. 1000 years
5. 4000 years
©2013 MFMER | slide-4
TB Pathogenesis
What is it?
• One of the oldest recorded human afflictions
• Bone TB from individuals who died 4,000 years
ago
• Assyrian clay tablets record hemoptysis 7th
century BC
• Hippocrates describes symptoms of consumption
from the 5th century BC
Clin. Microbiol. Rev. July 2003 vol. 16 no. 3 463-496
©2013 MFMER | slide-5
TB Pathogenesis
What is it?
• Until mid-1800s, many believed
TB was hereditary or a working
man’s disease
• 1865 Jean Antoine-Villemin
proved TB was contagious
• 1882 Robert Koch discovered
M. tuberculosis, the bacterium
that causes TB
Mycobacterium tuberculosis
Image credit: Janice Haney Carr
CDC.gov- Transmission and Pathogenesis of Tuberculosis
©2013 MFMER | slide-6
Mycobacterium tuberculosis
Recovery, an
Samurai Showdown
©2013 MFMER | slide-7
Mycobacterium tuberculosis
What is it?
• Caused by the Mycobacterium M. tuberculosis
• Small, aerobic, non-motile bacillus
• High lipid content- lipid bilayer
• Does not stain well
• Can live in a dry environment for weeks
• Can withstand some disinfectants
• Divides at the slow rate of 16-20 hours.
©2013 MFMER | slide-8
Mycobacterium tuberculosis
What is it?
• Can be identified under a regular light
microscope.
• Most mycobacterium retain stains
even after washes and therefore are
called “acid-fast” bacilli or AFB
• Common staining techniques are:
• Ziehl-Neelsen stain-bright red
• Auramine-rhodamine stain- fluorescence
microscopy
©2013 MFMER | slide-9
TB Pathogenesis
©2013 MFMER | slide-10
Mycobacterium tuberculosis
What it does
• TB is spread person to person
through the air via droplet nuclei
• M. tuberculosis may be expelled
when an infectious person:
• Coughs
• Sneezes
• Speaks
• Sings
• Transmission occurs when another
person inhales droplet nuclei
CDC.gov-Transmission and Pathogenesis of Tuberculosis
©2013 MFMER | slide-11
TB Pathogenesis
What it does
CDC.gov-Transmission and Pathogenesis of Tuberculosis
©2013 MFMER | slide-12
TB Pathogenesis
What it does
Droplet nuclei containing tubercle bacilli are
inhaled, enter the lungs, and travel to the small
alveoli
CDC.gov-Transmission and Pathogenesis of Tuberculosis
©2013 MFMER | slide-13
TB Pathogenesis
What it does
2
bronchiole
blood vessel
tubercle bacilli
alveoli
Tubercle bacilli multiply in alveoli, where
infection begins
CDC.gov-Transmission and Pathogenesis of Tuberculosis
©2013 MFMER | slide-14
TB Pathogenesis
What it does
3
brain
bone
lung
kidney
A small number of tubercle bacilli enter
bloodstream and spread throughout body
CDC.gov-Transmission and Pathogenesis of Tuberculosis
©2013 MFMER | slide-15
TB Pathogenesis
What it does
immune cells
form a barrier
• Within 2 to 8 weeks, MTB can be phagocytosed by alveolar
immune cells
• The phagocytosed immune cells transport the MTB to local
lymph nodes for T cells priming and cloning
• The immune cells form a barrier shell that keeps the bacilli
contained and under control (LTBI)
CDC.gov-Transmission and Pathogenesis of Tuberculosis
©2013 MFMER | slide-16
TB Pathogenesis
What it does
shell breaks
down and
tubercle
bacilli escape
and multiply
• If the immune system CANNOT keep tubercle bacilli under
control, bacilli begin to multiply rapidly and cause TB
disease
• This process can occur in different places in the body
CDC.gov-Transmission and Pathogenesis of Tuberculosis
©2013 MFMER | slide-17
Clinical Disease M. tuberculosis can cause
©2013 MFMER | slide-18
Who Does the Heavy Lifting?
What cells phagocytose the MTB bacilli
once they reach the alveoli?
A. CD4 T cells
B. B cells
C. Macrophages
D. Defensin cells
E. NK cells
©2013 MFMER | slide-19
Events following entry of bacilli
TB Pathogenesis
Stage1:
• Phagocytosis of MTB by Alveolar
macrophage
• Destruction of MTB, but some
evade destruction & continue to
multiply and then infect bystander
macrophages
Dr. h. c. Stefan H.E. Kaufmann
Max-Planck-Gesellschaft
©2013 MFMER | slide-20
Events following entry of bacilli
TB Pathogenesis
Stage 2:
• Influx of Polymononuclear cells (PMN) and
Monocytes-differentiate into Macrophage
• In some cases, it fails to eliminate the bacilli
completely
• Logarithmic growth of bacilli-little tissue
destruction
The PMNs come marching in
©2013 MFMER | slide-21
Events following entry of bacilli
TB Pathogenesis
Stage 3:
• Antigen specific T-cells are recruited to the site
and activate monocytoid cells and differentiate
into two types of Giant cells
• Epithiliod
• Langhan
• Infection is walled off from rest of the body
which prevents dissemination of bacilli.
Pharm & Therap 113;2007: 264
©2013 MFMER | slide-22
Events following entry of bacilli
TB Pathogenesis
Stage 4:
• Stage of Latency (Granuloma) disrupts under conditions
of failing immune surveillance & leads to endogenous
reactivation of dormant bacilli
• Characterised by caseation necrosis
Front. Immunol., 07 January 2013
©2013 MFMER | slide-23
The Great Tuberculosis Paradox
• Up to 50% of people with close and repeated
contact with confirmed index cases, even in
high burden areas, have no immunodiagnostic
evidence of Tb disease.
• Sterilizing innate immunity
• Likely related to host factors
©2013 MFMER | slide-24
The Great Tuberculosis Paradox
©2013 MFMER | slide-25
What factor does NOT impact the
likelihood of M. tuberculosis
transmission?
1. Intensity of exposure
2. Exposure duration
3. The gender of the infected individual
4. Recipient host factors
5. M. tuberculosis strain virulence
©2013 MFMER | slide-26
TB Immunopathogenesis
• Immune system vs. MTB
•
•
•
•
Local inflammation
Activation of a/b T cells
Enhanced cytokine response
A lot of IFN-g released
• MTB immune evasion techniques
• Suppressive cytokines (TGFb)
• Effector molecules
• Treg cells
Resp 2010. 15:433
©2013 MFMER | slide-27
TB Immunopathogenesis
The Achilles heel
• Increased susceptibility to TB with:
•
•
•
•
Suppressed CD4 or CD8 T cell levels- HIV
TNFa blockage
Hereditary IFN-g
IL-2 receptor abnormalities or inhibition
• Insight into immune requirements for
protection against MTB
©2013 MFMER | slide-28
Innate Immunity to M. tuberculosis
Toll-like receptor
Activate NK, T cells,
macrophages
NF-kB and cytokines
Vit D Receptor
Phagocytic killing of pathogens
Resp 2010.15:433
©2013 MFMER | slide-29
Innate Immunity to M. tuberculosis
• Promote bacterial killing with phagosomal
maturation, producing reactive nitrogen and
oxygen intermediates
• Several pathways and cell types mediate an
innate immune response to MTB
• Therefore, many individuals may fail to have an
immunodiagnostic evidence of MTB infection
despite prolonged or high-risk exposure
©2013 MFMER | slide-30
Adaptive Immunity to M. tuberculosis
• Mycobacterial infected macrophages and dendritic cells
present antigens to T cells and B cells.
• Macrophage apoptosis releases apoptotic vesicles with
MTB to uninfected DC for even greater antigen
presentation.
Pasteur institute
©2013 MFMER | slide-31
• Th1
Adaptive Immunity
CD4 T cell
• INFg, TNFa, IL2, GM-CSF
• Stimulation of CTL, macrophage activation
• Th2
• IL4, IL5, IL10, IL13
• B cell stimulation
• Suppress Th1
• Th17
• IL17, IL17F, IL21, Il22
• Defesin, recruit neutrophils and monocytes
• T reg
• TGFb
• Modulate T cell response
©2013 MFMER | slide-32
Adaptive Immunity to M. tuberculosis
Activates and recruits
Immune cells
Kills mycobacteria-infected cells
Resp 2010.15:433
©2013 MFMER | slide-33
Adaptive Immunity to M. tuberculosis
• B cells were not thought to have a significant
role in protecting against MTB
• Recent work showed that B cells were needed
in MTB infected mice by acting as an
intermediary for cellular immunity and the
complement pathway.
Eur J. Immunolo 2009;39:676
©2013 MFMER | slide-34
Adaptive Immunity to M. tuberculosis
• Memory T cells are created specific to MTB
antigens.
• Memory T cells are active and proliferate with
recall responses
• Specific, practical, clinical biomarkers of
protective immunity has not been established
Nat Med 2005;11:S33
©2013 MFMER | slide-35
Histology of TB disease
Collateral damage
Atlas of Pathology, 2nd edition, Romana
©2013 MFMER | slide-36
Histology of TB disease
Ziehl-Neelsen stain
H&E stain
• Delayed hypersensitivity reaction
• Central Caeseating necrosis
• Surrounded by lymphocytes, multi-nucleate giant cells and
epitheloid macrophages
• Organisms may be identified within the macrophages
National University of Singapore, Dept. of Pathology
©2013 MFMER | slide-37
Immunomodulation for Cure of TB
• Improve sterilizing immunity
• Decrease collateral damage of the immune
system
• 95% of bacterial sterilization occurs in 2 weeks,
but 6 months of therapy is needed.
• Is immune modulation needed to stop a
destructive immune pattern to a protective one?
©2013 MFMER | slide-38
Immunomodulation for Cure of TB
• Drive a Th1 response, turn off T reg
• IL2, INFg, steroids, thalidomide, TNFa antagonist-failed!
• IVIG dramatically improves mycobacterial sterilization in
a mouse model
• Many other agents in different stages of discovery and
clinical trials
Infect Immun 2005.73:6101
©2013 MFMER | slide-39
M. Tuberculosis vaccines
• MTB antigens ESAT-6, CFP-10 Ag85
• Found in latently infected, or exposure individuals
• Induce cytokine specific immune response
• Provide protective immunity in animal models
• Provide a protective antigen through a vaccine
or viral vector/gene therapy
©2013 MFMER | slide-40
M. Tuberculosis vaccines
Bacille Calmette Guerin
• BCG protective effect
• Age, background infection rates, virulence of MTB strain, coinfection with helminths, T cell immunity to helminths, malnution
• All factors that module the immune system
• Protects against MTB dissemination
• May protect against adult MTB infection in household
contacts
• Prevent primary infection and/or prevent transition from
LTBI to infection
©2013 MFMER | slide-41
Vaccine Candidates for MTB
Phase I and phase IIa trials
©2013 MFMER | slide-42
Challenges in vaccine development
• Children and adolescence
• HIV/TB co-infection – poor T cell response
• HIV/Helminth co-infection- strong Th2 response
• No good functional immune assays to predict a
sterilizing response
• ? Role of Aerosolized vaccination?
©2013 MFMER | slide-43
TB Pathogenesis
Immunopathogenesis!
La Miseria by Cristobal Rojas (1886).
World Health Organization
©2013 MFMER | slide-44